Suscripción a Biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicado 6 números por año

ISSN Imprimir: 0743-4863

ISSN En Línea: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Aerosol Treatment of Cystic Fibrosis

Volumen 20, Edición 5, 2003, 40 pages
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i5.10
Get accessGet access

SINOPSIS

Different aerosol therapies have been employed to treat the underlying cause and symptoms of cystic fibrosis (CF) during the past two decades. A summary of the main elements of the disease and aerosol treatments employed in clinical care and experimental trials are presented. Methods of aerosol generation and characterization are reviewed. Suggestions for improving the current treatments are provided.

CITADO POR
  1. Tam Jasmine M., McConville Jason T., Williams Robert O., Johnston Keith P., Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution, Journal of Pharmaceutical Sciences, 97, 11, 2008. Crossref

  2. Wang Ying-Ying, Lai Samuel K., Suk Jung Soo, Pace Amanda, Cone Richard, Hanes Justin, Addressing the PEG Mucoadhesivity Paradox to Engineer Nanoparticles that “Slip” through the Human Mucus Barrier, Angewandte Chemie International Edition, 47, 50, 2008. Crossref

  3. Plosker Greg L., Aztreonam Lysine for Inhalation Solution, Drugs, 70, 14, 2010. Crossref

  4. Wang Ying-Ying, Lai Samuel K., Suk Jung Soo, Pace Amanda, Cone Richard, Hanes Justin, Addressing the PEG Mucoadhesivity Paradox to Engineer Nanoparticles that “Slip” through the Human Mucus Barrier, Angewandte Chemie, 120, 50, 2008. Crossref

  5. Hindle Michael, Aerosol Drug Delivery, in Pharmaceutical Sciences Encyclopedia, 2010. Crossref

  6. Karnaukhova E., Ophir Y., Golding B., Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use, Amino Acids, 30, 4, 2006. Crossref

  7. Tang Benjamin C., Fu Jie, Watkins D. Neil, Hanes Justin, Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo, Biomaterials, 31, 2, 2010. Crossref

  8. Hickey Anthony J., Lu Dongmei, Ashley Elizabeth Dodds, Stout Jason, Inhaled Azithromycin Therapy, Journal of Aerosol Medicine, 19, 1, 2006. Crossref

  9. Vargas José M., McBride Amber A., Plumley John B., Fichou Yann, Memon Tosifa A., Shah Vichiksha, Cook Nathaniel C., Akins Brian A., Rivera Antonio C., Smolyakov Gennady A., O’Brien James R., Adolphi Natalie L., Smyth Hugh D. C., Osiński Marek, Synthesis and characterization of core/shell Fe3O4/ZnSe fluorescent magnetic nanoparticles, Journal of Applied Physics, 109, 7, 2011. Crossref

  10. Plosker Greg L., Aztreonam Lysine for Inhalation Solution in Cystic Fibrosis†, Pediatric Drugs, 13, 2, 2011. Crossref

  11. O’Riordan Thomas G, Aerosol delivery devices and obstructive airway disease, Expert Review of Medical Devices, 2, 2, 2005. Crossref

  12. Boylan Nicholas J., Suk Jung Soo, Lai Samuel K., Jelinek Raz, Boyle Michael P., Cooper Mark J., Hanes Justin, Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation, Journal of Controlled Release, 157, 1, 2012. Crossref

  13. Newman Stephen P., IMAGING PULMONARY DRUG DELIVERY, in Drug Delivery Applications of Noninvasive Imaging, 2013. Crossref

  14. Hickey Anthony J., Back to the Future: Inhaled Drug Products, Journal of Pharmaceutical Sciences, 102, 4, 2013. Crossref

  15. Connors Patricia M., Ulles Monica M., The Physical, Psychological, and Social Implications of Caring for the Pregnant Patient and Newborn With Cystic Fibrosis, The Journal of Perinatal & Neonatal Nursing, 19, 4, 2005. Crossref

  16. Hokey David A, Wachholder Robert, Darrah Patricia A, Bolton Diane L, Barouch Dan H, Hill Krystal, Dheenadhayalan Veerabadran, Schwander Stephan, Godin C Steven, Douoguih Macaya, Pau Maria Grazia, Seder Robert A, Roederer Mario, Sadoff Jerald C, Sizemore Donata, A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine, Human Vaccines & Immunotherapeutics, 10, 8, 2014. Crossref

  17. Hickey Anthony J., General Conclusion, in Inhaled Pharmaceutical Product Development Perspectives, 2018. Crossref

  18. Sultana Shaheen, Talegaonkar Sushma, Nishad Dhruv Kumar, Mittal Gaurav, Ahmad F.J., Bhatnagar Aseem, Alpha ketoglutarate nanoparticles: A potentially effective treatment for cyanide poisoning, European Journal of Pharmaceutics and Biopharmaceutics, 126, 2018. Crossref

  19. Price Dominique N., Kunda Nitesh K., Muttil Pavan, Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing, KONA Powder and Particle Journal, 36, 2019. Crossref

  20. Price Dominique N., Muttil Pavan, Delivery of Therapeutics to the Lung, in Lung Innate Immunity and Inflammation, 1809, 2018. Crossref

  21. Kukut Hatipoglu Manolya, Hickey Anthony J., Garcia-Contreras Lucila, Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs, International Journal of Pharmaceutics, 549, 1-2, 2018. Crossref

  22. Osiński Marek, Brandt Yekaterina I., Armijo Leisha M., Kopciuch Michael, Withers Nathan. J., Cook Nathaniel C., Adolphi Natalie L., Smolyakov Gennady A., Smyth Hugh D. C., Efficacy of Tobramycin Conjugated to Superparamagnetic Iron Oxide Nanoparticles in Treating Cystic Fibrosis Infections, MRS Proceedings, 1617, 2013. Crossref

  23. Garcia-Contreras Lucila, Bioavailability of inhaled compounds, in Inhalation Aerosols, 2019. Crossref

  24. Price Dominique N., Stromberg Loreen R., Kunda Nitesh K., Muttil Pavan, In Vivo Pulmonary Delivery and Magnetic-Targeting of Dry Powder Nano-in-Microparticles, Molecular Pharmaceutics, 14, 12, 2017. Crossref

  25. Suk Jung Soo, Lai Samuel K, Boylan Nicholas J, Dawson Michelle R, Boyle Michael P, Hanes Justin, Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine, Nanomedicine, 6, 2, 2011. Crossref

  26. Hickey Anthony James, Stewart Ian Edward, Inhaled antibodies: Quality and performance considerations, Human Vaccines & Immunotherapeutics, 18, 2, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain